Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lea Gutenkunst"'
Autor:
Michael Lübbert, Christoph Plass, Dieter Weichenhan, Dietmar Pfeifer, Olga Grishina, Nadja Blagitko-Dorfs, Ruth Meier, Ulrike Bönisch, Lea Gutenkunst, Dennis Zimmer, Julia Stomper, Bettina Berberich, Björn A. Grüning, Julia Schüler, Gabriele Greve
Supplementary Information: Supplementary Figures 1-11, Supplementary Figure Legends, Supplementary Tables 1-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49dc5821022c16703878c9fcebb89670
https://doi.org/10.1158/0008-5472.22426905.v1
https://doi.org/10.1158/0008-5472.22426905.v1
Autor:
Michael Lübbert, Christoph Plass, Dieter Weichenhan, Dietmar Pfeifer, Olga Grishina, Nadja Blagitko-Dorfs, Ruth Meier, Ulrike Bönisch, Lea Gutenkunst, Dennis Zimmer, Julia Stomper, Bettina Berberich, Björn A. Grüning, Julia Schüler, Gabriele Greve
Hypomethylating agents (HMA) have become the backbone of nonintensive acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) treatment, also by virtue of their activity in patients with adverse genetics, for example, monosomal karyotypes, often wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c6fdbf94468184f59ef641665a3b356
https://doi.org/10.1158/0008-5472.c.6512490.v1
https://doi.org/10.1158/0008-5472.c.6512490.v1
Autor:
Ruth Meier, Michael Lübbert, Julia Stomper, Nadja Blagitko-Dorfs, Dennis Zimmer, Dietmar Pfeifer, Bettina Berberich, Julia Schüler, Björn Grüning, Olga Grishina, Dieter Weichenhan, Lea Gutenkunst, Christoph Plass, Gabriele Greve, Ulrike Bönisch
Publikováno v:
Cancer research : an official organ of the American Association for Cancer Research
Hypomethylating agents (HMA) have become the backbone of nonintensive acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) treatment, also by virtue of their activity in patients with adverse genetics, for example, monosomal karyotypes, often wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba23c923ae865d603076c57f3b1a4d41
https://doi.org/10.1158/0008-5472.can-20-1430
https://doi.org/10.1158/0008-5472.can-20-1430
Autor:
Gabriele, Greve, Julia, Schüler, Björn A, Grüning, Bettina, Berberich, Julia, Stomper, Dennis, Zimmer, Lea, Gutenkunst, Ulrike, Bönisch, Ruth, Meier, Nadja, Blagitko-Dorfs, Olga, Grishina, Dietmar, Pfeifer, Dieter, Weichenhan, Christoph, Plass, Michael, Lübbert
Publikováno v:
Cancer research. 81(4)
Hypomethylating agents (HMA) have become the backbone of nonintensive acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) treatment, also by virtue of their activity in patients with adverse genetics, for example, monosomal karyotypes, often wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0597a4ed07a48224f56e40fafeea299d
https://pubmed.ncbi.nlm.nih.gov/33822747
https://pubmed.ncbi.nlm.nih.gov/33822747